(NASDAQ: CRON) Cronos Group's forecast annual revenue growth rate of 8.68% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Cronos Group's revenue in 2025 is $132,357,000.On average, 4 Wall Street analysts forecast CRON's revenue for 2025 to be $53,892,227,330, with the lowest CRON revenue forecast at $48,133,512,595, and the highest CRON revenue forecast at $59,382,916,779. On average, 4 Wall Street analysts forecast CRON's revenue for 2026 to be $70,360,466,744, with the lowest CRON revenue forecast at $52,421,917,185, and the highest CRON revenue forecast at $88,689,567,435.
In 2027, CRON is forecast to generate $59,248,904,136 in revenue, with the lowest revenue forecast at $56,924,742,005 and the highest revenue forecast at $60,991,068,500.